KR20070088808A - 융합된 피라졸 유도체 및 대사 관련 장애의 치료방법에서의 그의 용도 - Google Patents
융합된 피라졸 유도체 및 대사 관련 장애의 치료방법에서의 그의 용도 Download PDFInfo
- Publication number
- KR20070088808A KR20070088808A KR1020077016787A KR20077016787A KR20070088808A KR 20070088808 A KR20070088808 A KR 20070088808A KR 1020077016787 A KR1020077016787 A KR 1020077016787A KR 20077016787 A KR20077016787 A KR 20077016787A KR 20070088808 A KR20070088808 A KR 20070088808A
- Authority
- KR
- South Korea
- Prior art keywords
- tetrahydro
- diaza
- cyclopropa
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C1(*)C2(*)C(*)(*)C(*N*3)C3C12* Chemical compound *C1(*)C2(*)C(*)(*)C(*N*3)C3C12* 0.000 description 19
- SHHMCLMVMVYZAM-RRKGBCIJSA-N C(c1ccccc1)[n](c1c2CC3[C@H]1C3)nc2-c1n[nH]nn1 Chemical compound C(c1ccccc1)[n](c1c2CC3[C@H]1C3)nc2-c1n[nH]nn1 SHHMCLMVMVYZAM-RRKGBCIJSA-N 0.000 description 1
- SHHMCLMVMVYZAM-GHMZBOCLSA-N C(c1ccccc1)[n](c1c2C[C@@H]3[C@H]1C3)nc2-c1n[nH]nn1 Chemical compound C(c1ccccc1)[n](c1c2C[C@@H]3[C@H]1C3)nc2-c1n[nH]nn1 SHHMCLMVMVYZAM-GHMZBOCLSA-N 0.000 description 1
- DKSPRNJUDCWTID-QWWZWVQMSA-N C1[C@H]2c3n[nH]c(-c4n[nH]nn4)c3C[C@@H]12 Chemical compound C1[C@H]2c3n[nH]c(-c4n[nH]nn4)c3C[C@@H]12 DKSPRNJUDCWTID-QWWZWVQMSA-N 0.000 description 1
- SSDFWQQQLZIBPZ-JFGNBEQYSA-N CCCCC[C@H]1[C@H]2c3n[nH]c(C(OCC)=O)c3C[C@@H]12 Chemical compound CCCCC[C@H]1[C@H]2c3n[nH]c(C(OCC)=O)c3C[C@@H]12 SSDFWQQQLZIBPZ-JFGNBEQYSA-N 0.000 description 1
- OSXHVMAZRPAQKJ-JKMUOGBPSA-N CCOC(c1c([C@@H]2[C@H](C3)[C@H]2C)c3n[nH]1)=O Chemical compound CCOC(c1c([C@@H]2[C@H](C3)[C@H]2C)c3n[nH]1)=O OSXHVMAZRPAQKJ-JKMUOGBPSA-N 0.000 description 1
- IQCDRGYZHRHGFD-ZZMKPFPKSA-N CCOCC([C@@H]1CC2)[C@H]1[C@@H]2O Chemical compound CCOCC([C@@H]1CC2)[C@H]1[C@@H]2O IQCDRGYZHRHGFD-ZZMKPFPKSA-N 0.000 description 1
- OYSVSUKPKGBRBU-ULAWRXDQSA-N CC[C@H]([C@@H]1CC2)[C@H]1[C@@H]2O Chemical compound CC[C@H]([C@@H]1CC2)[C@H]1[C@@H]2O OYSVSUKPKGBRBU-ULAWRXDQSA-N 0.000 description 1
- APQANBAOGDTTDE-PRMYIZFSSA-N COC[C@@H]1[C@@H]2c3n[nH]c(C(O)=O)c3C[C@H]12 Chemical compound COC[C@@H]1[C@@H]2c3n[nH]c(C(O)=O)c3C[C@H]12 APQANBAOGDTTDE-PRMYIZFSSA-N 0.000 description 1
- OLLPSAAKXHXTMI-VXGBXAGGSA-N N#Cc1n[n](Cc2ccccc2)c2c1C[C@@H]1[C@H]2C1 Chemical compound N#Cc1n[n](Cc2ccccc2)c2c1C[C@@H]1[C@H]2C1 OLLPSAAKXHXTMI-VXGBXAGGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866804P | 2004-12-23 | 2004-12-23 | |
| US60/638,668 | 2004-12-23 | ||
| US67652105P | 2005-04-29 | 2005-04-29 | |
| US60/676,521 | 2005-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070088808A true KR20070088808A (ko) | 2007-08-29 |
Family
ID=36593187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077016787A Ceased KR20070088808A (ko) | 2004-12-23 | 2005-12-22 | 융합된 피라졸 유도체 및 대사 관련 장애의 치료방법에서의 그의 용도 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7241792B2 (https=) |
| EP (1) | EP1831178A2 (https=) |
| JP (1) | JP2008525476A (https=) |
| KR (1) | KR20070088808A (https=) |
| CN (2) | CN102321024A (https=) |
| AR (1) | AR055015A1 (https=) |
| AU (1) | AU2005319121A1 (https=) |
| BR (1) | BRPI0519262A2 (https=) |
| CA (1) | CA2589648A1 (https=) |
| CU (1) | CU23691B7 (https=) |
| EA (1) | EA013184B1 (https=) |
| GE (1) | GEP20105126B (https=) |
| GT (1) | GT200500379A (https=) |
| HN (1) | HN2005036256A (https=) |
| IL (1) | IL183654A0 (https=) |
| MA (1) | MA29148B1 (https=) |
| NI (1) | NI200700161A (https=) |
| NO (1) | NO20073766L (https=) |
| NZ (1) | NZ555721A (https=) |
| PA (1) | PA8658301A1 (https=) |
| PE (1) | PE20060949A1 (https=) |
| TN (1) | TNSN07236A1 (https=) |
| TW (1) | TW200635904A (https=) |
| WO (1) | WO2006069242A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220132664A (ko) * | 2009-08-28 | 2022-09-30 | 아레나 파마슈티칼스, 인크. | 칸나비노이드 수용체 조절제 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| DE602004022864D1 (de) | 2003-11-21 | 2009-10-08 | Arena Pharm Inc | 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen |
| PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| SI1901731T1 (sl) | 2005-06-28 | 2011-07-29 | Merck Sharp & Dohme | Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CN103492369B (zh) * | 2011-02-25 | 2019-03-29 | 艾尼纳制药公司 | 大麻素受体调节剂 |
| US9458136B2 (en) | 2011-02-25 | 2016-10-04 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
| WO2012116278A1 (en) * | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP3621619B1 (en) | 2017-05-08 | 2023-06-28 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of visceral pain |
| KR102919209B1 (ko) | 2018-08-10 | 2026-01-28 | 다이아핀 테라퓨틱스, 엘엘씨 | 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3105336A (en) * | 1961-05-16 | 1963-10-01 | Package Machinery Co | Converting wrapping machines to wrap different size articles |
| US4613610A (en) * | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| US5134155A (en) | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
| WO2000007996A2 (en) * | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| HUP0301493A2 (hu) | 2000-03-09 | 2003-08-28 | Ono Pharmaceutical Co., Ltd. | Indolszármazékok, eljárás előállításukra és alkalmazásuk |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| JP4279561B2 (ja) | 2001-05-23 | 2009-06-17 | メルク フロスト カナダ リミテツド | プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体 |
| US6884750B2 (en) | 2001-06-27 | 2005-04-26 | Rs Tech Corp. | Chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst |
| KR20040044856A (ko) | 2001-09-07 | 2004-05-31 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 유도체 화합물 |
| DE10148617A1 (de) * | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| ATE516277T1 (de) | 2002-03-19 | 2011-07-15 | Ono Pharmaceutical Co | Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten |
| WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| EP1551403B1 (en) * | 2002-10-10 | 2009-04-29 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| CA2528834A1 (en) * | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| PE20050483A1 (es) * | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| CN101103030B (zh) | 2004-02-14 | 2010-10-13 | 史密丝克莱恩比彻姆公司 | 具有hm74a受体活性的药物 |
| PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
-
2005
- 2005-12-15 PE PE2005001472A patent/PE20060949A1/es not_active Application Discontinuation
- 2005-12-20 GT GT200500379A patent/GT200500379A/es unknown
- 2005-12-21 HN HN2005036256A patent/HN2005036256A/es unknown
- 2005-12-21 TW TW094145549A patent/TW200635904A/zh unknown
- 2005-12-21 AR ARP050105438A patent/AR055015A1/es not_active Application Discontinuation
- 2005-12-22 WO PCT/US2005/046599 patent/WO2006069242A2/en not_active Ceased
- 2005-12-22 CN CN2011102214069A patent/CN102321024A/zh active Pending
- 2005-12-22 AU AU2005319121A patent/AU2005319121A1/en not_active Abandoned
- 2005-12-22 CN CN2011102214054A patent/CN102311378A/zh active Pending
- 2005-12-22 US US11/315,753 patent/US7241792B2/en not_active Expired - Lifetime
- 2005-12-22 GE GEAP200510188A patent/GEP20105126B/en unknown
- 2005-12-22 EP EP05857182A patent/EP1831178A2/en not_active Withdrawn
- 2005-12-22 NZ NZ555721A patent/NZ555721A/en not_active IP Right Cessation
- 2005-12-22 JP JP2007548472A patent/JP2008525476A/ja not_active Withdrawn
- 2005-12-22 BR BRPI0519262-5A patent/BRPI0519262A2/pt not_active IP Right Cessation
- 2005-12-22 EA EA200701361A patent/EA013184B1/ru not_active IP Right Cessation
- 2005-12-22 KR KR1020077016787A patent/KR20070088808A/ko not_active Ceased
- 2005-12-22 CA CA002589648A patent/CA2589648A1/en not_active Abandoned
- 2005-12-23 PA PA20058658301A patent/PA8658301A1/es unknown
-
2006
- 2006-11-17 US US11/601,184 patent/US7612106B2/en not_active Expired - Fee Related
-
2007
- 2007-06-04 IL IL183654A patent/IL183654A0/en unknown
- 2007-06-20 CU CU20070144A patent/CU23691B7/es not_active IP Right Cessation
- 2007-06-20 TN TNP2007000236A patent/TNSN07236A1/fr unknown
- 2007-06-21 NI NI200700161A patent/NI200700161A/es unknown
- 2007-07-12 MA MA30071A patent/MA29148B1/fr unknown
- 2007-07-19 NO NO20073766A patent/NO20073766L/no not_active Application Discontinuation
-
2009
- 2009-04-30 US US12/433,704 patent/US20090258892A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220132664A (ko) * | 2009-08-28 | 2022-09-30 | 아레나 파마슈티칼스, 인크. | 칸나비노이드 수용체 조절제 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090258892A1 (en) | 2009-10-15 |
| JP2008525476A (ja) | 2008-07-17 |
| CA2589648A1 (en) | 2006-06-29 |
| GEP20105126B (en) | 2010-12-10 |
| CU23691B7 (es) | 2011-09-21 |
| US20060205955A1 (en) | 2006-09-14 |
| GT200500379A (es) | 2006-10-25 |
| US20070073062A1 (en) | 2007-03-29 |
| BRPI0519262A2 (pt) | 2009-01-06 |
| US7612106B2 (en) | 2009-11-03 |
| AR055015A1 (es) | 2007-08-01 |
| WO2006069242A2 (en) | 2006-06-29 |
| EA013184B1 (ru) | 2010-02-26 |
| PE20060949A1 (es) | 2006-10-11 |
| PA8658301A1 (es) | 2006-10-13 |
| US7241792B2 (en) | 2007-07-10 |
| AU2005319121A1 (en) | 2006-06-29 |
| IL183654A0 (en) | 2007-09-20 |
| TNSN07236A1 (en) | 2008-11-21 |
| EA200701361A1 (ru) | 2007-12-28 |
| WO2006069242A3 (en) | 2006-08-31 |
| NO20073766L (no) | 2007-09-21 |
| CN102311378A (zh) | 2012-01-11 |
| CU20070144A7 (es) | 2010-01-22 |
| EP1831178A2 (en) | 2007-09-12 |
| NZ555721A (en) | 2011-02-25 |
| TW200635904A (en) | 2006-10-16 |
| HN2005036256A (es) | 2010-02-08 |
| CN102321024A (zh) | 2012-01-18 |
| NI200700161A (es) | 2008-04-21 |
| MA29148B1 (fr) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20070088808A (ko) | 융합된 피라졸 유도체 및 대사 관련 장애의 치료방법에서의 그의 용도 | |
| JP2010163448A (ja) | トリアゾール誘導体およびその代謝関連障害の処置方法 | |
| JP2007509181A5 (https=) | ||
| EP1701947B1 (en) | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof | |
| MX2007007578A (en) | Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders | |
| CN101087765A (zh) | 稠合吡唑衍生物和其在治疗代谢相关病症的方法中的用途 | |
| SA05260424B1 (ar) | مشتقات بيرازول مندمجة وطرق لمعالجة اضطرابات مرتبطة بالتمثيل الغذائي | |
| VON et al. | DISORDERS THEREOF | |
| HK1076468B (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
| HK1087411A (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20070720 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20101222 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120926 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20121230 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20120926 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |